{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:59:32Z","timestamp":1787032772167,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"DOI":"10.7759\/cureus.83301","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:37:35Z","timestamp":1746099455000},"source":"Crossref","is-referenced-by-count":1,"title":["Pregabalin Use in Treatment-Resistant Depression: A Case Report"],"prefix":"10.7759","author":[{"given":"Devon A","family":"McCoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadie R","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bogoyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57)","author":"Substance Abuse and Mental Health Services Administration","year":"2022","unstructured":"Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration, Rockville, MD; 2022."},{"key":"ref2","article-title":"Major depressive disorder","author":"Bains N","year":"2023","unstructured":"Bains N, Abdijadid S. Major depressive disorder. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S198774","article-title":"Management of treatment-resistant depression: challenges and strategies","volume":"16","author":"Voineskos D","year":"2020","unstructured":"Voineskos D, Daskalakis ZJ, Blumberger DM. Management of treatment-resistant depression: challenges and strategies. Neuropsychiatr Dis Treat. 2020, 16:221-34. 10.2147\/NDT.S198774","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2017.08.019","article-title":"Treatment resistant depression: a multi-scale, systems biology approach","volume":"84","author":"Akil H","year":"2018","unstructured":"Akil H, Gordon J, Hen R, et al.. Treatment resistant depression: a multi-scale, systems biology approach. Neurosci Biobehav Rev. 2018, 84:272-88. 10.1016\/j.neubiorev.2017.08.019","journal-title":"Neurosci Biobehav Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel \u03b12-\u03b4 (alpha2-delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor CP","year":"2007","unstructured":"Taylor CP, Angelotti T, Fauman E. Pharmacology and mechanism of action of pregabalin: the calcium channel \u03b12-\u03b4 (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res. 2007, 73:137-50. 10.1016\/j.eplepsyres.2006.09.008","journal-title":"Epilepsy Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001021","article-title":"Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments","volume":"7","author":"Krystal JH","year":"2002","unstructured":"Krystal JH, Sanacora G, Blumberg H, et al.. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol Psychiatry. 2002, 7:S71-80. 10.1038\/sj.mp.4001021","journal-title":"Mol Psychiatry"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200620080-00010","article-title":"Pregabalin: in the treatment of generalised anxiety disorder","volume":"20","author":"Frampton JE","year":"2006","unstructured":"Frampton JE, Foster RH. Pregabalin: in the treatment of generalised anxiety disorder. CNS Drugs. 2006, 20:685-93; discussion 694-5. 10.2165\/00023210-200620080-00010","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush AJ","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, et al.. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006, 163:1905-17. 10.1176\/ajp.2006.163.11.1905","journal-title":"Am J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-017-0827-5","article-title":"Use and safety of antiepileptic drugs in psychiatric inpatients-data from the AMSP study","volume":"268","author":"Druschky K","year":"2018","unstructured":"Druschky K, Bleich S, Grohmann R, et al.. Use and safety of antiepileptic drugs in psychiatric inpatients-data from the AMSP study. Eur Arch Psychiatry Clin Neurosci. 2018, 268:191-208. 10.1007\/s00406-017-0827-5","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S36453","article-title":"Pregabalin for the treatment of generalized anxiety disorder: an update","volume":"9","author":"Baldwin DS","year":"2013","unstructured":"Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R. Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat. 2013, 9:883-92. 10.2147\/NDT.S36453","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2021.09.063","article-title":"Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study","volume":"296","author":"Dold M","year":"2022","unstructured":"Dold M, Bartova L, Fugger G, et al.. Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. J Affect Disord. 2022, 296:485-92. 10.1016\/j.jad.2021.09.063","journal-title":"J Affect Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/337731-pregabalin-use-in-treatment-resistant-depression-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T11:37:36Z","timestamp":1746099456000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/337731-pregabalin-use-in-treatment-resistant-depression-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.83301","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}